摘要
目的探讨PBMCs中CPEB4、AKAP4、IRF4联合检测对早期非小细胞肺癌的诊断价值。方法纳入2017年10月至2019年10月我院收治的早期非小细胞肺癌患者100例为肿瘤组、肺部良性疾病患者100例为良性组、健康体检者100例为对照组。提取3组受试人员外周血单个核细胞(peripheral blood mononuclear cells,PBMCs)后通过免疫印迹检测PBMCs中CPEB4、AKAP4、IRF4、GAPDH的表达量,并用Image J进行定量分析。用受试者工作特征曲线(receiver operating characteristic curve,ROC)的AUC分析CPEB4、AKAP4、IRF4在早期非小细胞肺癌中的诊断意义。结果早期非小细胞肺癌患者血液PBMCs中CPEB4、AKAP4、IRF4的表达量均显著高于肺部良性疾病患者和健康体检者(P<0.05)。肿瘤组与良性组CPEB4、AKAP4、IRF4的灵敏度分别为93%、87%、91%,特异性分别为62%、87%、91%。肿瘤组与对照组CPEB4、AKAP4、IRF4的灵敏度分别为91%、90%、94%,特异性分别为91%、92%、94%。PBMCs中CPEB4、AKAP4、IRF4联合检测对早期非小细胞肺癌的诊断的的灵敏度为92.00%,特异性为91.50%,准确度为91.67%。结论PBMCs中CPEB4、AKAP4、IRF4的表达量检测可作为早期非小细胞肺癌的潜在标志。
Objective To investigate the value of CPEB4,AKAP4 and IRF4 in PBMCs in the diagnosis of early non-small cell lung cancer.Methods 100 patients with early NSCLC admitted to our hospital from October,2017 to October,2019 were included as the tumor group,100 patients with benign pulmonary disease as the benign group and 100 healthy subjects as the control group.Peripheral blood mononuclear cells(PBMCs)of the three groups were extracted and the expressions of CPEB4,AKAP4,IRF4 and GAPDH in PBMCs were detected by western blot,and were quantitatively analyzed by ImageJ.The AUC of receiver operating characteristic curve(ROC)was used to analyze the diagnostic performance of CPEB4,AKAP4 and IRF4 in early non-small cell lung cancer.Results The expression levels of CPEB4,AKAP4 and IRF4 in PBMCs in patients with early NSCLC were significantly higher than those in patients with benign pulmonary disease and healthy subjects(P<0.05).The sensitivities of CPEB4,AKAP4 and IRF4 in the tumor group and benign group were 93%,87%and 91%,and the specificities were 62%,87%and 91%,respectively.The sensitivities of CPEB4,AKAP4 and IRF4 in tumor group and control group were 91%,90%and 94%,and the specificities were 91%,92%,94%,respectively.The joint sensitivity,specificity and accuracy of CPEB4,AKAP4 and IRF4 in PBMCs were 92.00%,91.50%and 91.67%respectively.Conclusion The expressions of CPEB4,AKAP4 and IRF4 in PBMCs can be used as a potential diagnostic marker of early non-small cell lung cancer.
作者
李红霞
仝丽
陶虹
LI Hongxia;TONG Li;TAO Hong(Department of Oncology, Beijing Chest Hospital Affiliated to Capital Medical University,Beijing 101149, China)
出处
《标记免疫分析与临床》
CAS
2020年第8期1282-1286,共5页
Labeled Immunoassays and Clinical Medicine
基金
北京市科技计划项目(编号:Z171100002217018)。